Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capivasertib + Fulvestrant in Lobular Breast Cancer (LOBSTER)
NCT06607757Phase 2Recruiting
- Sponsor
- GBG Forschungs
- Start
- Dec 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capivasertib in invasive lobular carcinoma (ILC), sponsored by GBG Forschungs. Started Dec 2024; status: recruiting.
02
Drugs
capivasertib
03
Conditions
invasive lobular carcinoma (ILC)
Beyond the preview
Go deeper on NCT06607757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06607757.